Have a feature idea you'd love to see implemented?
Let us know!
TPST Tempest Therapeutics Inc
Price (delayed)
$0.8936
Market cap
$39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.53
Enterprise value
$34.62M
Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct
Highlights
The EPS has grown by 30% YoY and by 4.4% from the previous quarter
Tempest Therapeutics's debt has decreased by 16% YoY and by 12% from the previous quarter
The quick ratio is down by 26% since the previous quarter but it is up by 5% year-on-year
The equity has contracted by 32% from the previous quarter
The net income has contracted by 14% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of TPST
Market
Valuations
Earnings
Shares outstanding
43.64M
Market cap
$39M
Enterprise value
$34.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.97
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$34.07M
EBITDA
-$32.17M
Free cash flow
-$29.49M
Per share
Balance sheet
Liquidity
EPS
-$1.53
Free cash flow per share
-$1.14
Book value per share
$0.45
Revenue per share
$0
TBVPS
$1.31
Total assets
$33.84M
Total liabilities
$22.38M
Debt
$17.74M
Equity
$11.46M
Working capital
$9.58M
Debt to equity
1.55
Current ratio
1.69
Quick ratio
1.58
Net debt/EBITDA
0.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-82.6%
Return on equity
-187.4%
Return on invested capital
-175.7%
Return on capital employed
-171.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TPST stock price
How has the Tempest Therapeutics stock price performed over time
Intraday
-0.53%
1 week
-7.89%
1 month
-14.9%
1 year
-76.85%
YTD
-79.69%
QTD
-36.17%
Financial performance
How have Tempest Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.62M
Net income
-$35.52M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 16% YoY and by 13% QoQ
The net income has contracted by 14% YoY and by 12% from the previous quarter
Growth
What is Tempest Therapeutics's growth rate over time
Valuation
What is Tempest Therapeutics stock price valuation
P/E
N/A
P/B
1.97
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 30% YoY and by 4.4% from the previous quarter
The price to book (P/B) is 40% lower than the last 4 quarters average of 3.3 but 16% higher than the 5-year quarterly average of 1.7
The equity has contracted by 32% from the previous quarter
Efficiency
How efficient is Tempest Therapeutics business performance
TPST's return on invested capital has dropped by 64% year-on-year and by 29% since the previous quarter
The ROE has soared by 50% YoY and by 7% from the previous quarter
The company's return on assets rose by 8% YoY but it fell by 5% QoQ
Dividends
What is TPST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TPST.
Financial health
How did Tempest Therapeutics financials performed over time
The company's total assets is 51% higher than its total liabilities
The company's total assets rose by 41% YoY but it fell by 20% QoQ
The quick ratio is down by 26% since the previous quarter but it is up by 5% year-on-year
Tempest Therapeutics's debt is 55% more than its equity
The debt to equity has surged by 109% year-on-year and by 29% since the previous quarter
The equity has contracted by 32% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.